Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma

被引：2
|
作者：
Rosell, Rafael [1 ,2 ]
Karachaliou, Niki [2 ,3 ]
机构：
[1] Hosp Germans Ramon y Cajal, Catalan Inst Oncol, Barcelona 08916, Spain
[2] Germans Trias & Pujol Res Inst, Barcelona, Spain
[3] Univ Hosp Sagrat Cor, Inst Oncol, QuironSalud Grp, Barcelona, Spain
来源：
LANCET RESPIRATORY MEDICINE | 2018年 / 6卷 / 09期
关键词：
MUTATION; CANCER;
D O I：
10.1016/S2213-2600(18)30292-3
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：649 / 651
页数：4
相关论文
共 50 条
  • [1] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [2] Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy
    Chia, Brendan Seng Hup
    Nei, Wen Long
    Charumathi, Sabanayagam
    Fong, Kam Weng
    Tan, Min-Han
    CASE REPORTS IN ONCOLOGY, 2020, 13 (02): : 896 - 903
  • [3] Circulating tumor DNA sequencing to reveal the genomic complexity of advanced EGFR-mutant lung adenocarcinoma.
    Blakely, Collin M.
    Banks, Kimberly C.
    Lanman, Richard Burnham
    Riess, Jonathan
    Mack, Philip C.
    Bivona, Trever Grant
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment
    Del Re, Marzia
    Addeo, Alfredo
    Passaro, Antonio
    Petrini, Iacopo
    van Schaik, Ron H. N.
    Danesi, Romano
    PHARMACOGENOMICS, 2019, 20 (18) : 1255 - 1257
  • [5] Afatinib monotherapy in EGFR-mutant lung adenocarcinoma
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2013, 14 (09): : E345 - E345
  • [6] Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma
    Shulman, Katerina
    Kazarin, Olga
    Tannous, Elias
    Sofer, Orit
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (06): : 385 - 386
  • [7] Management of stage IA EGFR-mutant adenocarcinoma of the lung
    Pirker, Robert
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3260 - S3262
  • [8] Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
    Kim, Chul
    Xi, Liqiang
    Cultraro, Constance M.
    Wei, Fang
    Jones, Gregory
    Cheng, Jordan
    Shafiei, Ahmad
    Pham, Trinh Hoc-Tran
    Roper, Nitin
    Akoth, Elizabeth
    Ghafoor, Azam
    Misra, Vikram
    Monkash, Nina
    Strom, Charles
    Tu, Michael
    Liao, Wei
    Chia, David
    Morris, Clive
    Steinberg, Seth M.
    Bagheri, Hadi
    Wong, David T. W.
    Raffeld, Mark
    Guha, Udayan
    CANCERS, 2021, 13 (13)
  • [9] Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma
    Gautschi, Oliver
    Menon, Roopika
    Bertrand, Miriam
    Murer, Christian
    Diebold, Joachim
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : E13 - E15
  • [10] The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma
    Zhou, Wensheng
    Liu, Zhichao
    Wang, Yanan
    Zhang, Yanwei
    Qian, Fangfei
    Lu, Jun
    Wang, Huimin
    Gu, Ping
    Hu, Minjuan
    Chen, Ya
    Yang, Zhengyu
    Zhao, Ruiying
    Lou, Yuqing
    Han, Baohui
    Zhang, Wei
    CANCER MEDICINE, 2022, 11 (05): : 1299 - 1309
12345